The use of TNF-α blocking agents in rheumatoid arthritis: an overview

Bibliography

• HARRIS E: Clinical features of rheumatoid arthritis. In: Textbook of rheumatology Kelley W, Harris E, Ruddy S, Sledge C (Eds), WB Saunders & Co, Philadelphia, USA (1993):874–911.
   Google Scholar
• HARRIS E: Etiology and pathogenesis of rheumatoid arhtritis. In: Textbook of rheumatology Kelley W, Harris E, Ruddy S, Sledge C (Eds), WB Saunders & Co, Philadelphia, USA (1993):833–873.
   Google Scholar
• CHOY HS, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl. I Med. (2001) 344:907–916.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Ann. Rev Immunol (1996) 14:397–440.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYERJM: Inhibition of theproduction and effects of interleukin-1 and tumor necrosis factor-a in rheumatoid arthritis. Arthritic Rheum. (1995) 38:151–160.
   PubMed Web of Science ®Google Scholar
• MAINI RN, ELLIOTT MJ, BRENNAN F et al.: Monoclonal anti-TNF-a antibody as a probe of pathogenesis and therapy of rheumatoid arthritis. Immunol Rev (1995) 144:195–223.
   PubMed Web of Science ®Google Scholar
• •An excellent review on the importance of TNF-a as a therapeutic target in RA.
   Google Scholar
• FELDMANN M, BONDESON J, BRENNAN F et al.: The rationale for the current boom in anti-TNF-a treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNF-a and minimize hazards? Ann. Rheum. Dis. (1999) 58(Suppl. I):i27–i31.
   Google Scholar
• KOLLIAS G, DOUNI E, KASSIOTIS G et al.: On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev (1999) 169:175–194.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, MAINI RN: Discovery of TNF-a as atherapeutic target in rheumatoid arthritis. Preclinical and clinical studies. Joint Bone Spine (2002) 69:12–18.
   PubMed Web of Science ®Google Scholar
• FLIER JS, UNDERHILL LH: The tumor necrosis factor ligand and receptor families. N Engl. J. Med. (1996) 334:1717–1725.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA, MOLDAWER LL:The tumor necrosis factor (TNF) superfamily and its receptor. In: Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritic. Dinarello CA & Moldawer LL (Eds), Amgen, Thousand Oaks, USA (2000)77–97.
   Google Scholar
• IDRISS H, NAISMITH JH: TNF-a and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. (2000) 50:184–195.
   PubMed Web of Science ®Google Scholar
• KALDEN JR: Expanding role of biologic agents in rheumatoid arthritis." Rheumatol (2002) 29\(Suppl. 66):27–37.
   Google Scholar
• PALEOLOG E: The therapeutic potential of TNF-a blockade in rheumatoid arthritis. Expert Opin. Investig. Drugs (2003) 12:1087–1095.
   PubMed Web of Science ®Google Scholar
• MAINI RN, TAYLOR PC, PALEOLOG E et al.: Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arhritis. Ann. Rheum. Dis. (1999) 58(Suppl. I) d56–i60.
   Google Scholar
• HARRIMAN G, HARPER LK,SCHAIBLE TF: Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF-a treatment. Ann. Rheum. Dis. (1999) 58(Suppl. I):i61–i64.
   Google Scholar
• MARKHAM A, LAMB HM: Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs (2000) 59:1341–1359.
   Google Scholar
• •A review of the therapeutic use of inflixirnab in RA.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-a. Arthritic Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• MAINI RN, BREEDVELD FC,KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-a monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552–1563.
   Google Scholar
• KAVANAUGH A, STCLAIR EW, MCCUNE WJ et al.: Chimeric anti-tumornecrosis factor-a monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. Rheumatol (2000) 27:841–850.
   Web of Science ®Google Scholar
• MAINI RN, STCLAIR EW,BREED VELD FC et al., for the ATTRACT study group: Infliximab (chimeric anti-tumour necrosis factor-a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomittant methotrexate: a randomised Phase III trial. Lancet (1999) 354:1932–1939.
   Google Scholar
• •The most important placebo-controlled study with inflixirnab and concomittant methotrexate.
   Google Scholar
• LIPSKY P, VAN DER HEIJDE DMFM, STCLAIR EW et al. for the ATTRACT study group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1594–1602.
   PubMed Web of Science ®Google Scholar
• PAULUS H, EGGER M, WARD J et al.:Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, based on findings in patients treated with placebo. Arthritic Rheum. (1990) 33:477–484.
   PubMed Web of Science ®Google Scholar
• FELSON D, ANDERSON J, BOERS M et al.: American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis. Arthritic Rheum. (1995) 38:727–735.
   PubMed Web of Science ®Google Scholar
• ETANERCEPT: Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel. Drugs R&D (1999) 1:258–261.
   PubMedGoogle Scholar
• GARRISON L, MCDONNEL ND: Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(Suppl. I):i65–i69.
   Google Scholar
• SPENCER-GREEN G: Etanercept (Enbrel): update on therapeutic use. Ann. Rheum. Dis. (2000)59(Suppl. I): i46–i49.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N EngL I Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. (1999) 130:478–86.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosisfactor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• BATHON JM, MARTIN RW,FLEISCHMANN RIVI et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl. J. Med. (2000) 343:1586–1593.
   Google Scholar
• •A study of the use of etanercept in early RA.
   Google Scholar
• GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritic Rheum. (2002) 46:1443–1450.
   PubMed Web of Science ®Google Scholar
• MACHOLD KP, SMOLEN JS: Adalimumab - a new TNF-a antibody for treatment of inflammatory joint disease. Expert Opin. Biol. Ther. (2003) 3:351–360.
   PubMed Web of Science ®Google Scholar
• KEMPENI J: Preliminary results of early clinical trials with the fully human anti-TNF-a monoclonal antibody D2E7. Ann. Rheum. Dis. (1999)58\(Suppl. 1)170472.
   Google Scholar
• KEMPENI J: Update on D2E7: a fully human anti-tumour necrosis factor-a monoclonal antibody. Ann. Rheum. Dis. (2000) 59(Suppl. I):i44–i45.
   Google Scholar
• DEN BROEDER A, VAN DE PUTTE LBA, RAU R et al.: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-a antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatul (2002) 29:2288–2298.
   Google Scholar
• VAN GESTEL A, PREVO0 M, VANT HOF M et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. (1995) 39:34–40.
   Google Scholar
• DEN BROEDER AA, JOOSTEN LAB, SAXNE T et al.: Long term anti-tumour necrosis factor a monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61:311–318.
   PubMed Web of Science ®Google Scholar
• BARRERA P, VAN DER MAAS A, VAN EDE AE et al.: Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-a antibody compared with methotexate in long standing rheumatoid arthritis. Rheumatalogy (2002) 41:430–439.
   Google Scholar
• VVEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomittant methotrexate. The ARMADA trial. Arthritis Rheum. (2003) 48:35–45.
   PubMedGoogle Scholar
• •The most important trial using adalimurnab with concomittant methotrexate.
   Google Scholar
• RAU R, HERBORN G, SANDER 0 et al.:Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritis Rheum. (1999) 42(Suppl.):S400 (Abstract).
   Google Scholar
• KEYSTONE E, KAVANAUGH AF, SHARP J et al.: Adalimumab (D2E7), a fully human anti-TNF-a monoclonal antibody inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy (Abstract). Arthritis Rheum. (2003) 48(Suppl.):S205.
   Google Scholar
• ROSE-JOHN S, SCHOOLTINK H: CDP-870. CLIFF. Opin. Invest. Drugs (2003) 4:588–592.
   PubMedGoogle Scholar
• CHOY EHS, HAZLEMAN B, SMITH M et al.: Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. Rheumatology (2002) 41:1133–1137.
   PubMed Web of Science ®Google Scholar
• DARLINGTON C: PEG-sTNF-RI. Curr. Opin. Invest. Drugs (2003) 4:583–587.
   PubMedGoogle Scholar
• EDWARDS CK: PEGylated recombinanthuman soluble tumour necrosis factor receptor Type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.Ann. Rheum. Dis. (1999)a58 (Suppl. I):i73–i81.
   Google Scholar
• DAVIS M, FEIGE U, BENDELE AM et al.: Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor Type I: a clinical update. Ann. Rheum. Dis. (2000) 59(Suppl. I)143443.
   Google Scholar
• MORELAND LW, MCCABE DP, CALDWELL JR et al.: Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatul (2000) 27:601–609.
   PubMed Web of Science ®Google Scholar
• CDP571: anti-TNF monoclonal antibody,BAY 103356, BAY W 3356, Humicade. Drugs R&D (2003) 4:174–178.
   PubMedGoogle Scholar
• RANKIN ECC, CHOY EHS,KASSIMOS D et al.: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. I Rheumatul (1995) 34:334–342.
   Google Scholar
• CHOY EHS, RANKIN ECC, KASSIMOV D et al.: The engineered human anti-tumor necrosis factor-a antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.aRheumatul (1999) 26:2310–2317.
   PubMed Web of Science ®Google Scholar
• RAU R, SANDER 0, VAN RIEL P et al.:Intravenous human recombinant tumor necrosis factor receptor p55 IgG1 fusion protein Ro 45-2081(lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. I Rheumatul (2003) 30:680–690.
   Google Scholar
• FURST DE, WEISMAN M, PAULUS HE et al.: Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081(lenercept): results of a dose-finding study in rheumatoid arthritis. j. Rheumatula(2003) 30:2123–2126.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, COHEN SB, BAUMGARTNER SW et al.: Long term safety of etanercept in patients with rheumatoid arthritis. Rheumatul (2001) 28:1238–1244.
   PubMed Web of Science ®Google Scholar
• WEISMAN MH: What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. Rheumatul (2002) 29\(Suppl. 65):33–68.
   Google Scholar
• MARIETTE X: Inhibiteurs du TNF-a en2002: effets indésirables, surveillance, nouvelles indications en dehors de la polyarthrite rhumatoïde et des spondylarthropathies. Rev. Rhum. (2002) 69:982–991.
   Google Scholar
• KEANE J, GERSHON S, WISE RP et al.:Tuberculosis associated with infliximab, a tumor necrosis factor-a-neutralizing agent. N. Engl. J. Med. (2001)345:1098–1104.
   PubMed Web of Science ®Google Scholar
• •The first report of cases of tuberculosis occuring during anti-TNF-a treatment.
   Google Scholar
• ROTH S, DELMONT E, HEDIER P et al.: Anticorps anti-TNF-a (infliximab) et tuberculose: 'a propos de trois cas. Rev. Med. Interne (2002) 23:312–316.
   PubMedGoogle Scholar
• MAYORDOMO L, MARENCO JL, GOMEZ-MATEOS J et al.: Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand. I Rheumatul (2002) 31:44–45.
   PubMed Web of Science ®Google Scholar
• ELLERIN T, RUBIN RH, WEINBLATT: Infections and anti-tumor necrosis factor a therapy. Arthritic Rheum. (2003) 48(11):3013–3022.
   PubMed Web of Science ®Google Scholar
• MOHAN VP, SCANGA CA, YU K et al.:Effects of tumor necrosis factor alpha on the immune response in chronic persistent tuberculosis: a possible role for limiting pathology. Infect. Inman. (2001) 69:1847–1855.
   PubMed Web of Science ®Google Scholar
• GOMEZ-REINO JJ, CARMONA L, VALVERDE VR et al.: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report. Arthritic Rheum. (2003) 48:2122–2127.
   PubMed Web of Science ®Google Scholar
• FURST DE, CUSH J, KAUFMAN S et al: Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann. Rheum. Dis. (2002)6(Suppl. II):il62-ii63.
   Google Scholar
• ABITBOL V, BERENBAUM F,BREBAN M et al:. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine (2002) 69:170–172.
   Google Scholar
• •The French recommendations for the evaluation and the management of TB in patients receiving infliximab.
   Google Scholar
• KROESEN S, WIDMER AF, TYNDALL A et al: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-a therapy. Rheumatology (2003) 42:617–621.
   PubMed Web of Science ®Google Scholar
• LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor-a antagonists infliximab and etanercept. Arthritis Rheum. (2002) 46:2565–2570.
   PubMed Web of Science ®Google Scholar
• SLIFMAN NR, GERSHON SK, LEE JH et al.: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritic Rheum. (2003) 48:319–324.
   PubMed Web of Science ®Google Scholar
• MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occuring during anti-tumor necrosis factor-a therapy for inflammatory arthritides. Arthritic Rheum. (2001) 44:2862–2869.
   PubMed Web of Science ®Google Scholar
• ROBINSON WH, GENOVESE MC, MORELAND LW: Demyelinating andneurologic events reported in association with tumor necrosis factor-a antagonism. By what mechanisms could tumor necrosis factor-a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis. Arthritis Rheum. (2001) 44:1977–1983.
   Google Scholar
• BROWN SL, GREENE MH, GERSHON SK et al.: Tumor necrosis factor antagonist therapy and lymphoma development. Twenty-six cases reported to the food and Drug Administration. Arthritis Rheum. (2002) 46:3151–3158.
   PubMed Web of Science ®Google Scholar
• MARIETTE X, CAZALS-HATEM D, WARSZAWKIL J et al.: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood (2002) 99:3909–3915.
   PubMed Web of Science ®Google Scholar
• SHAKOOR N, MICHALSKA M, HARRIS CA et al.: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579–80.
   PubMed Web of Science ®Google Scholar
• DE BANDT M, VITECOQ 0, DESCAMPS V et al.: Anti-TNF-alpha induced systemic lupus syndrome. Chn. Rheumatol. (2003) 22:56–61.
   Google Scholar
• CHARLES PJ, SMEENK RJ, DE JONG J et al.: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. (2000) 43:2383–2390.
   Google Scholar
• DE RYCKE L, KRUITHOF E, VAN DAMME N et al: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritic Rheum. (2003) 48:1015–1023.
   PubMed Web of Science ®Google Scholar
• SHERGY WJ, ISERN RA, COOLEY DA et al.: Open label study to assess infliximab safety and timing onset of clinical benefit among patients with rheumatoid arthritis.Rheumatol. (2002) 29:667–677.
   Google Scholar
• KWON HJ, COTE TR, CUFFE MS et al: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138:807–811.
   PubMed Web of Science ®Google Scholar
• SMOLEN JS, BREEDVELD FC, BURMESTER GR et al.: Consensus statement on the initiation and continuation of tumor necrosis factorblocking therapies in rheumatoid artrhitis.Ann. Rheum. Dis. (2000) 59:504–505.
   PubMed Web of Science ®Google Scholar
• •The European guidelines for the use of TNF-a blockers in RA.
   Google Scholar
• PREVO0 MLL, VANTHOF MA, KUPER HH et al.: Modified disease activity scores that include twenty-eight joint counts. Arthritis Rheum. (1995) 38:44–48.
   Google Scholar
• MUGNIER B, BALANDRAUD N, DARQUE A et al.: Polymorphism at position-308 of the tumor necrosis factor-a gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. (2003) 48:1849–1852.
   PubMed Web of Science ®Google Scholar
• JOBANPUTRA P, BARTON P, BRYAN S et al.: The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. (2002) 6:1–110.
   PubMedGoogle Scholar
• KOBELT G, JONSSON L, YOUNG A et al.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and United-Kingdom based on the ATTRACT study. Rheumatology (2003) 42:326–335.
   PubMed Web of Science ®Google Scholar
• http://wwwsheumatology.org/research/hotline KAVANAUGH A, CUSH JJ, MATTESON E: FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Hotline 2003.
   Google Scholar
• http://www.rheumatology.org.uk BRITISH SOCIETY FOR RHEUMATOLOGY: Guidelines for prescribing TNF blockers in adults with rheumatoid arthritis. Report of a working party of the British Society for Rheumatology. April 2001.
   Google Scholar